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ABSTRACT
Background: Anemia is one of the most common hema-
tologic complications of cancer and cytotoxic treatment.
The economic burden associated with anemia in patients
with malignancy has not yet been extensively studied.
Methods: Patients receiving chemotherapy within 6
months of initial cancer diagnosis were identiﬁed in a
database of commercial health-care service claims and
encounters. Patients with anemia were identiﬁed through
a coded diagnosis of anemia, transfusion, or erythropoi-
etin treatment. Exponential conditional mean models and
a decomposition analysis were used to analyze mean 6-
month health-care expenditures.
Results: Twenty-six percent (26%) of 2760 cancer
patients with recently diagnosed invasive cancer treated
with chemotherapy had anemia. Mean (SD) 6-month
unadjusted total expenditures were $62,499 ($78,016)
for anemic patients and $36,871 ($52,308) for nonane-
mic patients (P < 0.0001), with inpatient services repre-
senting the largest cost differential between the groups.
The adjusted mean 6-month expenditure for the average
anemic  patient  receiving  chemotherapy  was  $57,209.
If  anemic  patients  had  the  same  average  health  status
as nonanemic patients, their predicted 6-month expendi-
tures would have been 19% lower ($46,237). Alterna-
tively, if anemic patients had the same expenditure
structure or parameter estimates as nonanemic patients,
their predicted expenditures would have been 51% lower
($27,847). Thus, for any given health status, treating a
patient who is anemic is associated with considerably
higher expenditures.
Conclusions: Anemia among cancer patients receiving
chemotherapy is associated with a substantial burden in
terms of direct medical costs. Implications for the treat-
ment of anemia are suggested by this research and should
be conﬁrmed in prospective studies.
Keywords: anemia, cancer, cost-of-illness.
Background
Approximately 8.4 million Americans have cancer
or a history of cancer, accounting for roughly 10%
of total health-care costs [1,2]. Anemia is one of the
most common hematologic complications associ-
ated with cancer, estimated to affect at least 50% of
patients with cancer at some point in their disease
course [3]. Anemia symptoms include fatigue, leth-
argy, tiredness, or lack of energy. Among patients
with cancer, the severity of anemia is inﬂuenced by
the type of malignancy and treatment regimen. A
high incidence of anemia has been reported across
the major nonmyeloid tumors treated with the most
commonly used chemotherapy agents and combina-
tions [4].
Although anemia is one of the most common
complications affecting patients with cancer,
researchers have only recently attempted to assess
the true prevalence and economic burden of ane-
mia. Two recent claims-based database studies esti-
mated anemia prevalence at between 9.5% and
27% of patients with cancer, with the highest rates
occurring among patients with hematologic malig-
nancies, those treated with chemotherapy, or having
distant metastasis [5,6]. Barnett et al. [6] found that
the additional cost of anemia in patients with cancer
was $3775 per year, with approximately 36% of the
costs attributable to the actual diagnosis and treat-
ment of the anemic condition.
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The main objective of this study is to assess the
impact of early anemia within 6 months of cancer
diagnosis on resource utilization and expenditures
in patients with cancer receiving chemotherapy. A
secondary objective is to identify demographic and
clinical characteristics associated with anemia in
this patient population.
Methods
The data used for this analysis were derived from
1999 Commercial Claims and Encounters and
Medicare Supplemental and Coordination of Bene-
ﬁts MarketScan® databases maintained by Medstat,
Inc. (Ann Arbor, MI, USA). The MarketScan data-
bases represent the medical experience of approxi-
mately three million covered employees and their
dependents, early retirees, Consolidated Omnibus
Reconciliation Act (COBRA) continuees, and a
small group of Medicare-eligible retirees. COBRA
requires employers with 20 or more employees to
continue to offer coverage in their group health plan
to certain former employees, retirees, spouses, and
dependent children. A variety of fee-for-service,
fully capitated, and partially capitated health plans,
including exclusive provider organizations, pre-
ferred provider organizations, point of service
plans, indemnity plans, and health maintenance
organizations, are represented in the databases.
Each database provides detailed cost and utilization
data for health-care services performed in both
inpatient and outpatient settings. Outpatient pre-
scription drug data were linked, via unique patient
identiﬁers, with inpatient and outpatient claims
ﬁles. The outpatient prescription drug ﬁle provides
information on drugs used (i.e., National Drug
Codes), therapeutic class, and pharmacy service
payments. Expenditures for all service types include
the total gross payment to a provider for speciﬁc
services before application of deductibles, copay-
ments, and coordination of beneﬁts, but after apply-
ing pricing guidelines such as fee schedules and
discounts.
Study Population Criteria
The population for this study consisted of patients
who have received a diagnosis of cancer, excluding
those with carcinoma in situ or nonmelanomatous
skin cancer, during the period January to June 1999
who also had a 3-month “clean” period free of can-
cer diagnosis, chemotherapy, or radiation treatment
before the initial 1999 cancer diagnosis, hereafter
referred to as the “preperiod,” and had at least one
claim for chemotherapy treatment in the 6 months
after the initial cancer diagnosis. Patients were fol-
lowed for up to 6 months after the initial 1999 can-
cer diagnosis, hereafter referred to as the “study
period.” The ﬁnal study population consisted of
2760 patients.
Outcome Measures and Covariates
This analysis compared health-care resource utiliza-
tion and expenditures of cancer patients receiving
chemotherapy treatment, by anemia status. Patients
were classiﬁed as anemic if they had at least one
claim with a diagnosis of anemia (ICD-9 CM code)
or anemia treatment, erythropoietin or red blood
cell transfusion, in the 3 months before or the
6 months after the initial cancer diagnosis. Patients
with transfusions were not excluded from the anal-
ysis. Otherwise, patients were classiﬁed as “non-
anemic,” patients with a diagnosis of anemia,
erythropoietin use or red blood cell transfusion
within 30 days before or after surgery were not clas-
siﬁed as having anemia for the purposes of this anal-
ysis. We note that hemoglobin values were not
available in these data.
Resource utilization was summarized for each
patient in the study period, and categorized into
four types of service: inpatient services, emergency
department services, outpatient services, and outpa-
tient pharmaceutical prescriptions. The associated
expenditures for these categories of service were
computed, as was an overall measure of total
expenditures. For patients with capitated insurance
coverage, payments were imputed using the mean
payments per procedure among all patients with
noncapitated insurance coverage in 1999.
Demographic characteristics available for pa-
tients included age, sex, geographic region, and plan
type. Clinical characteristics included summary
information on comorbidities, cancer type, and
treatments. A Charlson Comorbidity Index (CCI)
score for estimating a patient’s concurrent illnesses
was constructed from the preperiod and the study
period to adjust for expected resource utilization
associated with major comorbid health conditions.
The CCI score was calculated using a modiﬁcation
of the method developed by D’Hoore et al. [7] for
use in analyzing retrospective claims data, where
the CCI, covering 19 conditions, was adapted to the
International Classiﬁcation of Disease (ICD-9)
codes. Both primary and secondary diagnoses were
searched in the patient’s claims history for presence
of comorbidities. A categorical variable was created
to classify the type of initial cancer observed for
each patient in the study population. The following
groups were used to classify the initial cancer type:
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breast, central nervous system (CNS), endocrine,
gastrointestinal, genitourinary or gynecologic, head
and neck, hematologic (includes leukemia, lym-
phoma, and multiple myeloma), respiratory/tho-
racic, sarcoma, and other (secondary, not otherwise
speciﬁed, not elsewhere classiﬁed). Indicator varia-
bles were also created to identify patients treated
with radiation therapy or cancer-related surgery in
addition to their chemotherapy treatment during
the study period. Further, indicator variables were
created to identify patients with metastases involv-
ing lymph nodes or distant sites to serve as a proxy
for disease severity.
Statistical Analysis
To assess statistical differences between the anemia
and nonanemic cohorts, chi-square tests were
employed for categorical variables, whereas two-
tailed t-tests and median rank tests were used for
continuous variables. All multivariate analyses were
conducted using ﬁxed models based on a priori
hypotheses speciﬁed in an analysis plan. A logistic
regression model was estimated to determine which
patient characteristics are associated with anemia.
The model included demographic characteristics
(age and sex), presence of hematologic malignancy,
metastases to lymph nodes and to distant sites, CCI
score during the preperiod, use of radiotherapy or
cancer-related surgery, and type of health-care cov-
erage (capitated vs. noncapitated).
Health-care expenditure models commonly have
been estimated with log-transformed dollars as the
outcome or dependent variable [8,9]. Researchers
have routinely retransformed from log-dollars back
to  dollars  to  assess  mean  expenditures  through
the incorporation of a “smearing” term into the
retransformation [10]. Yet, this method is unbiased
only if the errors in the equation have constant var-
iance—a situation that is rare in the analyses of
health-care expenditures [11]. To account for the
non-negative nature of health-care costs, we used
exponential conditional mean (ECM) models to
analyze mean 6-month health-care expenditures.
During the examination of utilization and expen-
ditures, preliminary analysis revealed that the rela-
tionship between the total expenditures dependent
variable and the explanatory variables differed by
anemia status. A test of parameter equality was con-
ducted to test the hypothesis that the regression
coefﬁcients were equal for patients with and with-
out anemia treatment. The Wald test statistic
rejected the null hypothesis of parameter equality
(Wald chi-square with 15 degrees of freedom =
358.61; P < 0.01). Next, speciﬁcation testing was
conducted to determine the proper functional form
for the multivariate estimation of total expendi-
tures. Ordinary  least  squares  (OLS)  models  with
log transformation, ECM, and two-part models
were considered. Because no patients had zero total
expenditure in the 6 months after cancer diagnosis,
two-part models and OLS models with log trans-
formation are indistinguishable. As suggested by
Manning and Mullahy [12], to examine the appro-
priateness of ECM versus OLS with log transforma-
tion, we assessed the OLS log-scale residuals for
heteroscedasticity; chi-square statistic was 22.16 for
the anemic sample and 286.05 for the nonanemic
sample, and kurtosis, coefﬁcient of kurtosis was
5.81 for the anemic sample and 7.02 for the non-
anemic sample. This implies that the log-scale resid-
uals are both heteroscedastic and heavily tailed. The
performance of ECM and OLS with heteroscedastic
retransformation was compared using the Schwartz
and Akaike information criteria (AIC; see Manning
[13] and Ai and Norton [14] for OLS with hetero-
scedastic retransformation). Both tests slightly
favored ECM over OLS with log transformation
(anemic sample OLS: Schwarz criterion = 22.63
and AIC = 22.53, ECM: Schwarz criterion = 22.53
and AIC = 22.43; for the nonanemic sample OLS:
Schwarz criterion = 21.78 and AIC = 21.74, ECM:
Schwarz criterion = 21.29 and AIC = 21.25). This
justiﬁes use of the ECM model.
With parameter estimates from the ECM models,
we computed separate adjusted mean expenditures
for the anemia and no anemia comparison groups.
Multivariate analyses were conducted using STATA
software.
Each model included age, sex, preperiod CCI
score, cancer type, metastasis with lymph node
involvement,  metastasis  to  distant  site,  duration
of chemotherapy during the study period, cancer-
related surgery, and radiation therapy. Medicare
enrollment was not included in the models given its
correlation with age. Age, CCI scores, and duration
of chemotherapy (in days) were entered as contin-
uous variables. Further, a quadratic term for age
reﬂecting the observed nonlinear relationship with
expenditures was included. Given small sample
sizes in some of the cancer type subgroups, cancer
type was categorized as hematologic malignancy,
breast, gastrointestinal, respiratory/thoracic, geni-
tourinary/gynecology, and all remaining subgroups
combined; CNS, endocrine, head and neck,
melanoma, sarcoma, or other. The genitourinary/
gynecologic subgroup served as the reference group
in the models because it represented the most com-
mon cancer type in the study population. All other
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variables in the models were dichotomous indicator
variables.
A decomposition of differences in expenditures
between the anemic and nonanemic cohort was also
conducted [15–18].  In  this  analysis,  the  difference
in expenditures between anemic and nonanemic
patients was decomposed into two parts: 1) differ-
ences in health status proﬁle (different average
levels of the covariates); and 2) differences in their
expenditure structure (different parameter esti-
mates). To  evaluate  the  relative  magnitude  of
each component, expenditures for the anemia group
were predicted given the nonanemic patients’ health
status, holding the covariates ﬁxed at the average
level of the nonanemic patients, and given the non-
anemic patients’ expenditure structure, holding the
parameter coefﬁcients at the level of the nonanemic
patients.
Results
Prevalence of  Anemia and Factors Associated 
with Anemia
The  ﬁnal  study  sample  included  2760  patients
with cancer receiving chemotherapy treatment, 731
(26%) of which had evidence of anemia in the
3 months before or the 6 months after the initial
cancer diagnosis. Of these 731 patients, 412 (56%)
were classiﬁed as anemic solely on the basis of hav-
ing an anemia diagnosis during the preperiod or
study  period.  The  remaining  44%  had  evidence
of  being  treated  for  anemia  with  erythropoietin
or blood transfusions during this period. In total,
17.1% of the study population had capitated insur-
ance coverage; the proportion of patients with this
type of insurance was similar in both the anemic
and nonanemic groups.
Descriptive analyses indicated that the anemic
patients in the sample were slightly younger in age
than nonanemic patients (Table 1). The mean age
of all patients was 62.4 years; whereas the mean
age of anemic patients was 61.2 years. The aver-
age CCI score among the study population in the
study period was 7.3, with anemic patients hav-
ing signiﬁcantly (P < 0.0001) higher CCI scores
(9.4) than nonanemic patients (6.6), indicating
greater pre-existing comorbidity. The most com-
mon cancer types were genitourinary/gynecologic
cancer (28.8%) followed by breast cancer
(19.2%) and gastrointestinal cancer (16.4%).
Anemic patients were signiﬁcantly more likely to
have gastrointestinal, hematologic, respiratory/
thoracic and sarcoma cancers than nonanemic
patients, and were more likely to have metastasis
to distant sites (all, P < 0.05). With respect to can-
cer-related treatments, anemic patients were sig-
niﬁcantly more likely to have received a longer
duration of chemotherapy treatment in the follow-
up period than nonanemic patients (93 days vs.
74 days; P < 0.0001). Rates of radiation and can-
cer-related surgery did not vary signiﬁcantly by
anemia status.
A logistic regression was performed to identify
factors associated with anemia among cancer
patients receiving chemotherapy treatment
(Table 2). This analysis indicated that anemia was
positively associated (P < 0.05) with each of the fol-
lowing: hematologic malignancies, metastasis to a
distant site, a preperiod CCI score >0, female sex,
and  noncapitated  health  insurance.  The  analysis
did not ﬁnd a signiﬁcant association with anemia
for age ≥ 65 years, radiation therapy, cancer-related
surgery, or metastasis to the lymph nodes during the
study period.
Table 1 Demographic and clinical characteristics of  study
population by anemia status
Anemia
(N = 731)
n (%)
No anemia 
(N = 2029) 
n (%) P value*
Men 323  (44.2) 1113  (54.9) <0.0001
Age ≥ 65 years 310  (42.4) 998  (49.2) 0.0016
Capitated insurance 
coverage
118  (16.1) 359  (17.7) 0.3416
Cancer type
Breast 96  (13.1) 434  (21.4) <0.0001
CNS 8  (1.1) 31  (1.5) 0.3946
Endocrine 8   (1.1) 14  (0.7) 0.2918
Gastrointestinal 166  (22.7) 286  (14.1) <0.0001
Genitourinary/
gynecologic
89  (12.2) 705   (34.7) <0.0001
Head & neck 5  (0.7) 34  (1.7) 0.0514
Hematologic† 170 (23.3) 157  (7.7) <0.0001
Melanoma 0  (0.0) 24  (1.2) 0.0031
Respiratory/thoracic 93  (12.7) 185  (9.1) 0.0055
Sarcoma 13  (1.8) 14   (0.7) 0.0104
Other 83  (11.4) 145  (7.2) 0.0004
Metastasis 301  (41.2) 590  (29.1) <0.0001
Lymph node involvement 109  (14.9) 258  (12.7) 0.1339
Distant sites 238  (32.6) 406  (20.0) <0.0001
Cancer-related treatments
Radiation therapy 273  (37.4) 795  (39.2) 0.3823
Surgery 423  (57.9) 1128  (55.6) 0.2884
Mean (SD) Mean (SD)
Age
61.2 (14.7) 62.8 (13.7) 0.0118
CCI score 9.4 (6.8) 6.6 (5.7) <0.0001
Duration (Days) of  
chemotherapy in study
period
92.6 (54.0) 74.4 (55.6) <0.0001
*The P value represents the results of  the statistical comparison of  anemic to
nonanemic patients using chi-square tests for categorical variables and t-tests for
continuous variables.
†Includes lymphoma, leukemia, and multiple myeloma.
CCI, Charlson Comorbidity Index.
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Health-Care Utilization and Expenditures
Tables 3 and 4 present study period health-care uti-
lization and expenditures for patients by anemia
status. Rates of inpatient, outpatient, and outpa-
tient prescription drug utilization were signiﬁcantly
higher for the anemic than the nonanemic group.
Anemic patients had about twice as many hospital
admissions and emergency department visits, and
one third more outpatient service days and prescrip-
tion drug claims than nonanemic patients (all
P < 0.0001). The mean length of stay among
patients who were hospitalized in the study period
was 10.9 days for anemic patients, compared with
6.4 days for nonanemic patients (P < 0.0001).
Patients with anemia had signiﬁcantly higher
total expenditures than nonanemic patients across
each of the four service areas: inpatient, emergency
department, outpatient, and outpatient prescription
drugs (Table 4). Mean 6-month unadjusted total
expenditures  were  $62,499  for  anemic  patients
and $36,871 for nonanemic patients (P < 0.0001)
(Table 4). Although patients with anemia repre-
sented just 26% of the study population, their
health-care expenditures accounted for 46% of
total hospitalization expenditures and 38% of total
expenditures across the full study population.
Erythropoietin treatment accounted for less than
2% of total expenditures in the anemia group.
Inpatient services were the largest driver of differ-
ences in costs between the two groups. Mean inpa-
tient costs for  anemic  patients  were  more  than
twice  that  for nonanemic patients ($30,639 vs.
$13,152) (Table 4).
Total expenditures were modeled as a function of
sociodemographic characteristics, preperiod comor-
bidity, cancer type and treatments, metastases, and
duration of chemotherapy for the anemic and non-
anemic cohorts (Table 5). Based on parameter
estimates from Table 5, the mean (SE) adjusted 6-
month expenditures for the anemic and nonanemic
cohorts were $63,694 ($33,623) and $28,955
($41,332), respectively. For patients with anemia,
hematologic malignancy (P < 0.01), and respira-
tory/thoracic cancer (P < 0.05) were signiﬁcantly
associated  with  increased  expenditures  relative
to the genitourinary/gynecologic cancer reference
group. Cancer-related surgery also signiﬁcantly
increased expenditures (P < 0.01). The other cancer
type group included CNS, endocrine, head and
neck, melanoma, sarcoma, and other unspeciﬁed
cancers. For the nonanemic cohort, higher comor-
bidity scores, longer duration of chemotherapy,
Table 2 Probability of  anemia: logistic regression analysis
Odds ratio Lower CI* Upper CI*
Preperiod CCI† score >0 1.386§ 1.118 1.719
Male 0.682§ 0.567 0.821
Age > 65 0.825 0.676 1.005
Hematologic malignancy 4.464§ 3.464 5.752
Metastasis to lymph node 1.158 0.891 1.506
Metastasis to distant site 2.267§ 1.856 2.768
Cancer-related surgery 1.180 0.973 1.431
Radiation therapy 1.000 0.831 1.204
Capitated health insurance 0.759‡ 0.590 0.977
*Lower (upper) CI = lower (upper) values of  the 95% conﬁdence interval for the
odds ratio.
†Dummy variable for Charlson Comorbidity Index score greater than 0 in
preperiod.
‡P < 0.05.
§P < 0.01.
Table 3 Study period health-care utilization by anemia
status
Anemia 
(N = 731)
No anemia 
(N = 2029) 
Mean SD Mean SD
Inpatient hospital admissions 1.5* 1.8 0.8 1.1
Number of  hospital days† 8.0* 12.0 3.3 7.2
Number of  hospital days 
(among users)‡
10.9* 12.8 6.4 8.9
Emergency department visits 1.3* 2.8 0.7 1.8
Outpatient service days 35.5* 18.1 25.1 15.6
Outpatient drug prescriptions 25.0* 17.5 18.6 15.4
*Mean (median) for anemic patients was signiﬁcantly different from mean
(median) for nonanemic patients, t-test P < 0.0001 (Mann–Whitney U-test
P < 0.0001).
†Number of  hospital days indicates mean (SD) number of  days of  hospitalization
among all patients who were analyzed.
‡Number of  hospital days (among users) indicates mean (SD) number of  days of
hospitalization among patients who were hospitalized.
Table 4 Six-month unadjusted health-care expenditures by anemia status
Anemia (N = 731) No anemia (N = 2029) 
Mean SD Mean SD
Inpatient services ($) 30,639† 74,432 13,152 46,322
Emergency department ($) 588* 2,248 318 1,590
Outpatient services ($) 30,354† 24,418 22,607 22,373
Outpatient prescription drugs ($) 2,409† 3,997 1,324 2,156
Total ($) 62,499† 78,016 36,871 52,308
*Mean (median) for anemic patients was signiﬁcantly different from mean (median) for nonanemic patients, t-test P < 0.002 (Mann–Whitney U-test P < 0.0001).
†Mean (median) for anemic patients was signiﬁcantly different from mean (median) for nonanemic patients, t-test P < 0.0001 (Mann–Whitney U-test P < 0.0001).
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each cancer type (except for other), metastasis to
distant sites, and radiotherapy were signiﬁcantly
associated with increased expenditures whereas
other cancer types and metastasis to lymph nodes
were associated with decreased expenditures
(P < 0.01).
A decomposition of the difference in costs by ane-
mia status was also conducted. Evaluating the cov-
ariates at the sample means, the predicted 6-month
expenditures for chemotherapy patients with anemia
were $57,209. Applying the health status of the non-
anemic patients (i.e., nonanemic average levels of
covariates) to the anemia estimated model, predicted
6-month expenditures were $46,237, approximately
19% lower. Applying the expenditure structure of
the nonanemic patients (i.e., the nonanemic param-
eter estimates) to the anemia cohort (i.e., anemic
average levels of covariates), predicted 6-month
expenditures were $27,847, approximately 51%
lower than the original prediction. The implication
of this analysis is that for any given health status,
treating a patient who, in addition, is anemic is asso-
ciated with considerably higher expenditures.
Discussion
Using a retrospective database of the reimbursed
health-care claims of roughly three million covered
lives, this study estimates the burden of anemia in
terms of direct medical costs among chemotherapy-
treated cancer patients (N = 2760). Twenty-six per-
cent of these patients (n = 731) were identiﬁed as
anemic by diagnosis codes or treatment for anemia.
Anemic patients’ 6-month mean (SE) health-care
expenditures, adjusted for covariates, were $63,694
($33,623) compared with $28,955 ($41,332) for
nonanemic patients.
Although patients with anemia represent just
more than a quarter of patients undergoing chem-
otherapy, their health-care expenditures accounted
for 46% of inpatient expenditures and 38% of all
expenditures. The expenditure structure of anemic
and nonanemic patients differed, most likely result-
ing from the ﬁnding that inpatient-related services
were the most important driver of expenditure dif-
ferentiation between the anemic and nonanemic
cohorts. Erythropoietin treatment accounted for
less than 2% of total expenditures in the anemia
group. In multivariate analyses that controlled for
age, sex, preperiod comorbidity (CCI), cancer type,
cancer severity, and cancer treatment regimen, total
expenditures for anemic patients were higher than
those of nonanemic patients. This study provides
detailed information concerning the nature and rea-
son that anemic patients are more likely than non-
anemic patients to have increased utilization of all
types of health-care services. Differences in health
status between anemic and nonanemic patients only
accounted for 19% of the anemic patients’ expen-
ditures, whereas the remaining expenditures were
primarily driven by the nature of incurred expenses,
namely inpatient services.
Table 5 Parameter estimates from multivariate speciﬁcation for mean 6-month direct expenditures: exponential conditioned
mean model speciﬁcation
Anemia No anemia 
Parameter
estimate
Standard
error
Parameter
estimate
Standard
error
Constant 11.936§ 0.208 10.975§ 0.151
Age (year) -0.018* 0.008 -0.003 0.006
Age-squared (year) -0.000 0.000 -0.000§ 0.000
Men 0.039 0.079 0.077 0.056
Preperiod CCI score 0.067 0.044 0.481§ 0.013
Chemotherapy days/month 0.000 0.001 0.004§ 0.000
Cancer type†
Hematologic malignancy 0.627§ 0.177 0.174§ 0.133
Breast cancer -0.260 0.249 0.416§ 0.121
Gastrointestinal cancer 0.070 0.197 1.256§ 0.089
Respiratory/thoracic cancer 0.465* 0.200 0.836§ 0.105
Other cancer‡ -0.476§ 0.181 -0.714§ 0.108
Metastasis—lymph node -0.196 0.132 -0.352§ 0.071
Metastasis—distant site 0.164 0.092 0.194§ 0.039
Cancer-related surgery 0.356§ 0.087 -0.087 0.052
Radiotherapy 0.150 0.085 0.208§ 0.051
Model characteristics N = 731; Adjusted R2 = 0.484 N = 2029; Adjusted R2 = 0.602
*P < 0.05.
†Relative to the genitourinary/gynecologic cancer reference group.
‡CNS, endocrine, head and neck, melanoma, sarcoma, and other unspeciﬁed cancers.
§P < 0.01.
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The strongest factor associated with anemia was
hematologic malignancies, a ﬁnding that has been
shown in other research [19,20]. The next strongest
factors associated with anemia were the comorbid-
ity indicators and staging; greater preperiod CCI
scores and evidence of metastasis to distant sites.
Another factor that was found to be associated
with increased incidence of anemia was sex; women
were more likely than men to have anemia diag-
nosed. Groopman and Itri [4] have reviewed the lit-
erature and found that the incidence of anemia is
associated with several different tumor types, stage,
and speciﬁc chemotherapeutic regimens. It is note-
worthy that age is not associated with increased
incidence of anemia, either in this research or in
other published studies [4,21,22]. Finally, the rela-
tionship between anemia and noncapitated health
insurance, while not strong, was present. The latter
ﬁnding  may  reﬂect  a  selection  bias.  Individuals
with long-term illnesses and comorbidities are more
likely to have established relationships with medi-
cal providers and therefore may be more likely to
select fee-for-service programs to preserve those
relationships.
Our study has several limitations that stem from
the retrospective nature of the data. First, while the
sample was drawn from more than three million
lives, it may not be representative of the general
population, or even of those with health insurance.
Second, for untreated anemic patients, we rely on
identifying the anemic population based on physi-
cian and facility coding of an anemia diagnosis for
patients with low hemoglobin values. Untreated
low-grade anemic patients may be less likely to
receive an ICD-9 diagnostic code for anemia in their
health-care claims, and thus would be included in
our cohort of nonanemic patients. Additionally,
because of data availability, this study only looks at
early anemia—anemia that occurs within the ﬁrst
6 months after initial cancer diagnosis. We are una-
ble to track disease progression over time, which
may affect our results.
Another limitation of this study is the absence of
hemoglobin or hematocrit data, because this would
allow for deﬁnitive determination of patients’ ane-
mic status, and a determination of the undertreat-
ment of anemia. Nevertheless, the presence of an
anemia diagnosis code in these data does not nec-
essarily indicate that anemia is severe enough to
require treatment; it may simply indicate that the
anemia was noted in the medical chart and resulted
in its entry on the health-care claim. Inclusion of
data on actual patient hemoglobin concentration
would enable researchers to examine the effective-
ness of anemia treatment on changes in hemoglobin
and determine if changes in health-care utilization
and expenditures result from such treatment.
Finally, the study has some methodological limi-
tations. Although the ECM model used for the anal-
ysis does  have  several  advantages,  it  does  not ﬁt
well with highly skewed data, such as health-care
expenditure. Hence, although the model chosen
allows for decomposition of the drivers of skew-
ness; there was a trade-off between bias and robust-
ness in its selection.
Additional  research  on  the  effects  of  anemia
with regard to disease prevalence and health-care
resource utilization for all patients with cancer is
warranted. Results of studies by Glaspy et al. [21]
and Demetri et al. [22] demonstrated a relationship
between an increase in hemoglobin concentrations
and an improvement in quality of life. Additional
research is needed to investigate further the impact
of anemia treatment or the lack of it on utilization
and costs, for both patients with and without chem-
otherapy treatment.
In summary, this analysis of reimbursed health-
care claims suggests that anemia is associated with a
substantial burden in terms of direct medical care
costs. Anemic cancer patients receiving chemother-
apy utilize considerably more health-care resources,
both inpatient and outpatient services, even after
controlling for many possible confounders. A pro-
spective trial with broad inclusion criteria that is
designed to assess the health-care utilization and
costs associated with ameliorating anemia of chem-
otherapy patients in general oncology practice
appears to be warranted.
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